Friday, July 10, 2026
🇺🇸 FDA

pharma · Hemophagocytic lymphohistiocytosis (HLH) · Multiple sclerosis

PARItec

Pari Pharma GmbH

PARItec clinical programs — 139 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Website Investor relations
Starnberg, DE HQ
28 Employees
EMA registrant Type
Company details
Status
Public
HQ
Starnberg, DE
Employees
28
Programs
248
Drugs
362
Patents
0
Official website ↗ All projects Drug pipeline News & analysis
Intelligence · Clinical Programs

PARItec projects

139 ClinicalTrials.gov programs sponsored by PARItec.

PARItec has 139 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

All phases Phase III Phase II Phase I NDA / BLA filed Approved programs

139 programs

Clinical programs

Page 2 of 3

  1. APHP211429

    Pari Pharma GmbH

    patients suffering from acute myocarditis confirmed on Cardiac magnetic resonance imaging.

    phase 3 small molecule active

    1 trial

  2. APHP220668

    Pari Pharma GmbH

    Major depressive disorder with current severe major depressive episode

    phase 3 small molecule active

    1 trial

  3. APHP220670

    Pari Pharma GmbH

    Pregnant women with singleton pregnancies hospitalized for threatened late miscarriage with intact membranes

    phase 3 small molecule active

    1 trial

  4. APHP220672

    Pari Pharma GmbH

    Post-aggressive immunosuppression

    phase 3 small molecule active

    1 trial

  5. APHP220674

    Pari Pharma GmbH

    respiratory distress due to upper airway obstruction in child

    phase 3 small molecule active

    1 trial

  6. APHP220676

    Pari Pharma GmbH

    Severe hyponatremia and a high risk of rapid SNa overcorrection

    phase 3 small molecule active

    1 trial

  7. APHP220763

    Pari Pharma GmbH

    Catheter related bloodstream infections due to Staphylococcus aureus

    phase 3 small molecule active

    1 trial

  8. APHP220790

    Pari Pharma GmbH

    Chondrocalcinosis

    phase 3 small molecule active

    1 trial

  9. APHP220791

    Pari Pharma GmbH

    CytoMegaloVirus infections, Kidney transplant

    phase 3 small molecule active

    1 trial

  10. APHP220797

    Pari Pharma GmbH

    Sickle cell disease

    phase 3 small molecule active

    1 trial

  11. APHP220800

    Pari Pharma GmbH

    Patients in ICU with invasive mechanical ventilation and HSV throat reactivation with 1 or no organ failures.

    phase 3 small molecule active

    1 trial

  12. APHP220805

    Pari Pharma GmbH

    incisional hernia

    phase 3 small molecule active

    1 trial

  13. APHP220814

    Pari Pharma GmbH

    Community-acquired pneumonia

    phase 3 small molecule active

    1 trial

  14. APHP220818

    Pari Pharma GmbH

    Acute mesenteric ischemia

    phase 3 small molecule active

    1 trial

  15. APHP220822

    Pari Pharma GmbH

    Subjects with PBC with a non-optimal response to UDCA.

    phase 3 small molecule active

    1 trial

  16. APHP220826

    Pari Pharma GmbH

    Adult patients discharged alive from ICU with a decreased eGFR, and/or an AKI during ICU stay and/or an elevated NT-proBNP at discharge.

    phase 3 small molecule active

    1 trial

  17. APHP220827

    Pari Pharma GmbH

    Acute Kidney Injury, Liver transplantation

    phase 3 small molecule active

    1 trial

  18. APHP220832

    Pari Pharma GmbH

    Myotonic dystrophy type 1 (DM1)

    phase 3 small molecule active

    1 trial

  19. APHP220917

    Pari Pharma GmbH

    patient with colorectal cancer with hepatic metastasis

    phase 3 small molecule active

    1 trial

  20. APHP230813

    Pari Pharma GmbH

    Very preterm neonate (gestational age at birth < 32 WG) with corrected gestational age <45 WG) with indication for sedation in the context of invasive mechanical ventilation

    phase 3 small molecule active

    1 trial

  21. APHP230823

    Pari Pharma GmbH

    Adults aged at least 18 years with painful base-of-thumb osteoarthritis

    phase 3 small molecule active

    1 trial

  22. APHP230824

    Pari Pharma GmbH

    Uncomplicated candidemia

    phase 3 small molecule active

    1 trial

  23. APHP230825

    Pari Pharma GmbH

    PEDIATRIC ACUTE MYOCARDITIS

    phase 3 small molecule active

    1 trial

  24. APHP230833

    Pari Pharma GmbH

    Heart failure

    phase 3 small molecule active

    1 trial

  25. APHP230836

    Pari Pharma GmbH

    Patients presenting to ENT emergencies with a unilateral sudden sensorineural hearing loss (SSNHL). SSNHL is defined according to the American ENT society guidelines criteria as a subset of SSNHL that is sensorineural in nature, occurs within a 72 hour window, and consists of a decrease in hearing of ≥30 decibels affecting at least 3 consecutive frequencies: 1. A history of an idiopathic and unilateral sudden decrease in hearing > 72 hours and <15 days. 2. A unilateral sensorineural hearing loss demonstrable on a pure‐tone audiogram at the time of entry into the trial. 3. No other neurological signs except the eight cranial nerve defect; no other types of hearing loss as conductive forms of hearing impairment. 4. No history of fluctuating sensorineural hearing loss or otologic disease.

    phase 3 small molecule active

    1 trial

  26. APHP230841

    Pari Pharma GmbH

    Population of study participants Pregnant women with PPROM at 22 to 33 weeks’ gestation

    phase 3 small molecule active

    1 trial

  27. APHP230844

    Pari Pharma GmbH

    Adult patients with severe cardiogenic shock on venoarterial ECMO support for less than 24 hours.

    phase 3 small molecule active

    1 trial

  28. APHP230847

    Pari Pharma GmbH

    Pulmonary arterial hypertension

    phase 3 small molecule active

    1 trial

  29. APHP230852

    Pari Pharma GmbH

    Patients diagnosed at the study sites with rifampicinresistant tuberculosis during the recruitment period will be evaluated for study inclusion.

    phase 3 small molecule active

    1 trial

  30. APHP230855

    Pari Pharma GmbH

    Patients presenting with acute myocarditis proven by cardiac magnetic resonance imaging (CMRi) or by histological evidence on endomyocardial biopsy (EMB)

    phase 3 small molecule active

    1 trial

  31. APHP230864

    Pari Pharma GmbH

    Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy

    phase 3 small molecule active

    1 trial

  32. APHP230869

    Pari Pharma GmbH

    insomnia, Depressive episode

    phase 3 small molecule active

    1 trial

  33. APHP231089

    Pari Pharma GmbH

    Multiple Myeloma Multiple myeloma (MM) is a B cell malignancy and is one of the most frequent primary neoplasms of the bone marrow

    phase 3 small molecule active

    1 trial

  34. APHP240792

    Pari Pharma GmbH

    Septic arthritis

    phase 3 small molecule active

    1 trial

  35. APHP240804

    Pari Pharma GmbH

    Adult patients with symptomatic and inflammatory Hand osteoarthritis HOA.

    phase 3 small molecule active

    1 trial

  36. APHP240889

    Pari Pharma GmbH

    Aortic bioprothesis implanted patient for valvular heart disease

    phase 3 small molecule active

    1 trial

  37. APHP240909

    Pari Pharma GmbH

    Patient with stabilized SSc-ILD (as defined by a decline of FVC ≤ 5%) following RTX induction treatment

    phase 3 small molecule active

    1 trial

  38. APHP240920

    Pari Pharma GmbH

    Cutaneous lupus erythematosus

    phase 3 small molecule active

    1 trial

  39. APHP240938

    Pari Pharma GmbH

    Adult patients admitted to the ICU and receiving unplanned invasive mechanical ventilation

    phase 3 small molecule active

    1 trial

  40. APHP241011

    Pari Pharma GmbH

    Adult patients with stage IV non squamous non-small cell lung cancer (NSCLC)

    phase 3 small molecule active

    1 trial

  41. APHP241013

    Pari Pharma GmbH

    Young Adults and adults with R/R B-cell acute lymphoblastic leukemia (BCP-ALL) or a B cell lymphoma (BCL)

    phase 3 small molecule active

    1 trial

  42. APHP251262

    Pari Pharma GmbH

    Neisseria gonorrhoeae Infections

    phase 3 small molecule active

    1 trial

  43. COLCHICINE OPOCALCIUM 1 mg, comprimé sécable

    Pari Pharma GmbH

    Stroke, Ischemic, TIA, Cardiac Disease, Atherosclerosis, Myocardial Infarction, Coronary Syndrome, Cerebral Infarction

    phase 3 small molecule active

    1 trial

  44. CYCLOPHOSPHAMIDE

    Pari Pharma GmbH

    The study will involve adult women and men from 16 French centers who have hematological malignancies and are candidates for haploidentical HSCT

    phase 3 small molecule active

    1 trial

  45. D20180102

    Pari Pharma GmbH

    Vascular calcification and type 1 diabetes

    phase 3 small molecule active

    1 trial

  46. D20180135

    Pari Pharma GmbH

    Eosinophilic granulomatosis with polyangiitis (EGPA), formerly called Churg-Strauss syndrome

    phase 3 small molecule active

    1 trial

  47. D20180177

    Pari Pharma GmbH

    Pancreatic adenocarcinoma (PAC)

    phase 3 small molecule active

    1 trial

  48. D24-P009

    Pari Pharma GmbH

    Aneurysmal Subarachnoid Hemorrhage

    phase 3 small molecule active

    1 trial

Frequently asked questions

How many clinical projects does PARItec have?

139 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.